cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Theravance Biopharma Inc
8 own
7 watching
Current Price
$10.67
$-0.19
(-1.75%)
logo-tbph
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
718.8M
52-Week High
52-Week High
11.8297
52-Week Low
52-Week Low
7.53
Average Volume
Average Volume
0.32M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization718.8M
icon52-Week High11.8297
icon52-Week Low7.53
iconAverage Volume0.32M
iconDividend Yield--
iconP/E Ratio--
What does the Theravance Biopharma Inc do?
Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria. Its product candidates include TD-1792 that is in phase III clinical trials for the treatment of skin and soft tissues infections; TD-6450, a multivalent NS5A inhibitor, which is in Phase II study for Hepatitis C Virus; and Revefenacin (TD-4208), a long acting muscarinic antagonist that is in Phase III clinical studies for chronic obstructive pulmonary diseases. The company's product candidates also comprise Axelopran, an oral peripherally active mu opioid receptor antagonist that is in Phase II clinical trials for opioid induced constipation; Velusetrag (TD-5108), an oral and investigational medicine, which is in Phase II studies for gastrointestinal motility disorders; TD-8954, a selective 5-HT4 receptor agonist for gastrointestinal motility disorders; and TD-1473, a pan-Janus kinase inhibitor, which has completed phase I clinical studies for ulcerative colitis. In addition, it develops TD-0714, a Neprilysin inhibitor that has completed phase I clinical studies for heart failure and chronic kidney diseases; and TD-9855, an investigational norepinephrine and serotonin reuptake inhibitor, which is in Phase II clinical studies for neurogenic orthostatic hypotension. Further, the company focuses on various drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol for the treatment of COPD and asthma; the Inhaled Bifunctional Muscarinic Antagonist-Beta2 Agonist program, as monotherapy; and in combination with other therapeutically active components, such as an inhaled corticosteroid. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
Read More
How much money does Theravance Biopharma Inc make?
News & Events about Theravance Biopharma Inc.
Ticker Report
2hours ago
StockNews.com cut shares of Theravance Biopharma (NASDAQ:TBPH Get Rating) from a buy rating to a hold rating in a research note issued to investors on Tuesday. A number of other research analysts also recently commented on the stock. HC Wainwright increased their target price on shares of ...
PR Newswire
2 months ago
Theravance Biopharma, Inc. Announces Preliminary Results of Tender Offer Theravance Biopharma, Inc. Announces Preliminary Results of Tender Offer PR Newswire DUBLIN, Nov. 18, 2022 DUBLIN, Nov. 18, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ('Theravance Biopharma' or the...
Ticker Report
3 months ago
Theravance Biopharma (NASDAQ:TBPH Get Rating) and SIGA Technologies (NASDAQ:SIGA Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, profitability, ...
PR Newswire
4 months ago
Thinking about buying stock in Reunion Neuroscience, bluebird bio, Reviva Pharmaceuticals, Theravance Biopharma, or Broadwind? Thinking about buying stock in Reunion Neuroscience, bluebird bio, Reviva Pharmaceuticals, Theravance Biopharma, or Broadwind? PR Newswire NEW YORK, Sept. 19, 2022 NEW...
PR Newswire
6 months ago
Thinking about buying stock in Selecta Biosciences, Adial Pharmaceuticals, Exela Technologies, Theravance Biopharma, or Organogenesis? Thinking about buying stock in Selecta Biosciences, Adial Pharmaceuticals, Exela Technologies, Theravance Biopharma, or Organogenesis? PR Newswire NEW YORK, July...
Frequently Asked Questions
Frequently Asked Questions
What is Theravance Biopharma Inc share price today?
plus_minus_icon
Can Indians buy Theravance Biopharma Inc shares?
plus_minus_icon
How can I buy Theravance Biopharma Inc shares from India?
plus_minus_icon
Can Fractional shares of Theravance Biopharma Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Theravance Biopharma Inc stocks?
plus_minus_icon
What is today’s traded volume of Theravance Biopharma Inc?
plus_minus_icon
What is today’s market capitalisation of Theravance Biopharma Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Theravance Biopharma Inc?
plus_minus_icon
What percentage is Theravance Biopharma Inc down from its 52-Week High?
plus_minus_icon
What percentage is Theravance Biopharma Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$10.67
$-0.19
(-1.75%)
logo-tbph
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00